COMPANY RESEARCHArvinas is a U.S. clinical-stage biotechnology company developing medicines based on targeted protein degradation. Its PROTAC platform is designed to use cellular protein-disposal machinery to reduce selected disease-associated proteins. Research priorities include oncology and neuroscience, with programs intended to assess potential therapeutic uses of selective protein degradation. Arvinas is headquartered in New Haven, Connecticut, and its common stock trades on Nasdaq under ARVN. The company combines proprietary discovery technologies with clinical-development work and selected partnerships.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Arvinas is a U.S. clinical-stage biotechnology company developing medicines based on targeted protein degradation. Its PROTAC platform is designed to use cellular protein-disposal machinery to reduce selected disease-associated proteins. Research priorities include oncology and neuroscience, with programs intended to assess potential therapeutic uses of selective protein degradation. Arvinas is headquartered in New Haven, Connecticut, and its common stock trades on Nasdaq under ARVN. The company combines proprietary discovery technologies with clinical-development work and selected partnerships.
Nasdaq: ARVN
PROTAC · targeted protein degradation
oncology · neurology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| vepdegestrant（VEPPANU） | ER / BCL6 / LRRK2 · ESR1-mutated ER+/HER2− advanced or metastatic breast cancer progressing after at least one line of endocrine therapy (United States) | Approved | Regulatory validation limited to the approved jurisdiction / indication |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 3 / 3 related items
Arvinas announced an ASH poster on preliminary Phase 1 findings for oral BCL6 degrader ARV-393, also called zaloblideg, in relapsed or refractory non-Hodgkin lymphoma. The December 14 presentation will cover safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in T-cell lymphomas. The announcement itself does not provide numerical response results.
Arvinas said it will prioritize a Phase 1b study of its LRRK2 degrader ARV-102 in progressive supranuclear palsy in the European Union and United Kingdom. Trial applications and regulatory authorization remain pending. The company continues discussions with US and Japanese regulators, while the US investigational new drug application remains on hold.
Arvinas presented final Phase 1 findings for its brain-penetrant LRRK2 degrader ARV-102 in 24 patients with Parkinson’s disease treated for 28 days. Exploratory changes in eye movement measurements correlated with reductions in cerebrospinal fluid LRRK2 and changes in pathway biomarkers. The trial was not designed to establish clinical efficacy or effects on disease progression.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.